E-LIB Suche - Ergebnisse für: Torka, Pallawi

1

Health-related quality of life outcomes reporting associate..:

Gupta, Medhavi ; Akhtar, Othman Salim ; Bahl, Bhavyaa...
BMJ Oncology. 3 (2024) 1 - p. e000369 , 2024

Link: https://doi.org/10.1136/..

2

Perspectives on geriatric oncology research presented at th..:

Abdallah, Maya ; Akhtar, Othman Salim ; Major, Ajay...
Journal of Geriatric Oncology. 15 (2024) 5 - p. 101762 , 2024

Link: https://doi.org/10.1016/..

3

High-Grade B-Cell Lymphoma, Not Otherwise Specified: CNS In..:

Epperla, Narendranath ; Zayac, Adam Stephen ; Landsburg, Daniel J....
Blood Advances. , 2024

Link: https://doi.org/10.1182/..

4

Impact of race and social determinants of health on outcome..:

Karmali, Reem ; Machhi, Rushad ; Epperla, Narendranath...
Blood Advances. 8 (2024) 10 - p. 2592-2599 , 2024

Link: https://doi.org/10.1182/..

5

Outcomes of marginal zone lymphoma treated with ibrutinib i..:

Epperla, Narendranath ; Zhao, Qiuhong ; Moyo, Tamara...
Blood Advances. 8 (2024) 3 - p. 549-552 , 2024

Link: https://doi.org/10.1182/..

6

CLL-578 BTK Inhibitors: A Double-Edged Sword in Richter's T..:

Mundluru, Jahnavi ; Ingawale, Sushrut ; Dhanjal, Kirit..
Clinical Lymphoma Myeloma and Leukemia. 24 (2024) - p. S360 , 2024

Link: https://doi.org/10.1016/..

7

Rituximab and lenalidomide for the treatment of relapsed or..:

Cassanello, Giulio ; Drill, Esther ; Rivas-Delgado, Alfredo...
Haematologica. , 2024

Link: https://doi.org/10.3324/..

8

BTK Inhibitors: A Double-Edged Sword in Richter's Transform..:

Mundluru, Jahnavi ; Ingawale, Sushrut ; Dhanjal, Kirit..
Clinical Lymphoma Myeloma and Leukemia. 24 (2024) - p. S184 , 2024

Link: https://doi.org/10.1016/..

9

Population Pharmacokinetics and Pharmacodynamics of Carfilz..:

Lin, Lan-Hsi ; Ghasemi, Mohammad ; Burke, Sarah M....
Targeted Oncology. 18 (2023) 5 - p. 685-695 , 2023

Link: https://doi.org/10.1007/..

10

Impact of cumulative dose of brentuximab vedotin on outcome..:

Steiner, Raphael E. ; Hwang, Steven R. ; Khurana, Arushi...
Blood Advances. 7 (2023) 24 - p. 7485-7493 , 2023

Link: https://doi.org/10.1182/..

11

Carfilzomib combined with rituximab, ifosfamide, carboplati..:

Torka, Pallawi ; Groman, Adrienne ; Wong, Jerry...
Blood Advances. 7 (2023) 7 - p. 1146-1155 , 2023

Link: https://doi.org/10.1182/..

12

Effect of cumulative dose of brentuximab vedotin maintenanc..:

Wagner, Charlotte B. ; Boucher, Ken ; Nedved, Adrienne...
Haematologica. 108 (2023) 11 - p. 3025-3032 , 2023

Link: https://doi.org/10.3324/..

13

Multivariable Analyses of Prognostic Factors for Progressio..:

Hassoun, Hani ; Jacobus, Susanna J ; Richardson, Paul G....
Transplantation and Cellular Therapy. 29 (2023) 2 - p. S396-S397 , 2023

Link: https://doi.org/10.1016/..

14

Older patients with primary central nervous system lymphoma..:

David, Kevin A. ; Sundaram, Suchitra ; Kim, Seo‐Hyun...
American Journal of Hematology. 98 (2023) 6 - p. 900-912 , 2023

Link: https://doi.org/10.1002/..

15

Postibrutinib relapse outcomes for patients with marginal z..:

Epperla, Narendranath ; Zhao, Qiuhong ; Chowdhury, Sayan Mullick...
Blood Advances. 7 (2023) 1 - p. 88-91 , 2023

Link: https://doi.org/10.1182/..